China Establishes Biosimilar Approval Rules; Abandons Drug Price Controls

China formally accepted the Biosimilar Approval process that was issued in draft form last fall, making only minor alterations to the plan. The government also said it would discontinue issuing price controls on drugs. The changes were released as part of an annual government policy disclosure by China's Premier, Li Keqiang, as China's National People's Conference, the nation's legislature, began its annual two-week session. More details.... Share this with colleagues: // //